I am a
Home I AM A Search Login

Papers of the Week


2022 Jul 29


Osteoporos Int

Sickle cell bone disease and response to intravenous bisphosphonates in children.

Authors

Grimbly C, Escagedo DP, Jaremko JL, Bruce A, Alos N, Robinson ME, Konji VN, Page M, Scharke M, Simpson E, Pastore YD, Girgis R, Alexander RT, Ward LM
Osteoporos Int. 2022 Jul 29.
PMID: 35904681.

Abstract

Children with sickle cell disease (SCD) have the potential for extensive and early-onset bone morbidity. This study reports on the diversity of bone morbidity seen in children with SCD followed at three tertiary centers. IV bisphosphonates were effective for bone pain analgesia and did not trigger sickle cell complications.